Anabolics america

BUY Genesis Bolde 250 Quantity:                       10 ml x 250 mg/ml = 2500mg Chemical Contents:         Boldenone Undecylenate Manufacturer:                 Genesis Meds Boldenone is a regarded as a lean form of Deca. Boldenone Undecylenate is a derivative of testosterone, which exhibits strong anabolic and moderately androgenic properties. The undecylenate ester greatly extends the activity of the drug (the undecylenate ester is only one carbon atom longer than decanoate), so that clinically injections would need to be repeated every two or three weeks. Boldenone exhibits a pronounced effect on lean body weight, appetite and general disposition. This compound is also said to show a marked ability for increasing red blood cell production. Not a rapid mass builder, instead Boldenone will be looked at to provide a slow but steady gain of strength and quality muscle mass. The most positive effects are seen when it is used for longer periods, usually lasting more than 8-12 weeks in duration. The muscle gained should not be the smooth bulk seen with some androgens, but very defined and solid. Since water is not contributing greatly to the diameter of the muscle, much of the size gained can be retained after use has been discontinued. Although it stays active for a much longer time, Boldenone is often injected at least once per week. Typical in the range of 200-400mg per week for men, 50-75 mg per week for women. BUY Genesis offers Boldenone Undecylenate 250mg/ml...

Cachexia is a serious, however underestimated and underrecognised medical consequence of malignant cancer, chronic heart failure (CHF), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), cystic fibrosis, rheumatoid arthritis, Alzheimer's disease, infectious diseases, and many other chronic illnesses. The prevalence of cachexia is high, ranging from 5% to 15% in CHF or COPD to 60% to 80% in advanced cancer. By population prevalence, the most frequent cachexia subtypes are in order: COPD cachexia, cardiac cachexia (in CHF), cancer cachexia, and CKD cachexia. In industrialized countries (North America, Europe, Japan), the overall prevalence of cachexia (due to any disease) is growing and currently about 1%, ., about nine million patients. The relative prevalence of cachexia is somewhat less in Asia, but is a growing problem there as well. In absolute terms, cachexia is, in Asia (due to the larger population), as least as big a problem as in the Western world. Cachexia is also a big medical problem in South America and Africa, but data are scarce. A consensus statement recently proposed to diagnose cachexia in chronic diseases when there is weight loss exceeding 5% within the previous 3-12 months combined with symptoms characteristic for cachexia (., fatigue), loss of skeletal muscle and biochemical abnormalities (., anemia or inflammation). Treatment approaches using anabolics, anti-catabolic therapies, appetite stimulants, and nutritional interventions are under development. A more thorough understanding of the pathophysiology of cachexia development and progression is needed that likely will lead to combination therapies being developed. These efforts are greatly needed as presence of cachexia is always associated with high-mortality and poor-symptom status and dismal quality of life. It is thought that in cancer, more than 30% of patients die due to cachexia and more than 50% of patients with cancer die with cachexia being present. In other chronic illnesses, one can estimate that up to 30% of patients die with some degree of cachexia being present. Mortality rates of patients with cachexia range from 10% to 15% per year (COPD), to 20% to 30% per year (CHF, CKD) to 80% in cancer.

The Body is a service of Remedy Health Media, LLC, 750 3rd Avenue, 6th Floor, New York, NY 10017. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.

Anabolics america

anabolics america


anabolics americaanabolics americaanabolics americaanabolics americaanabolics america